Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? a retrospective database analysis

Diabetes Care

Volumn 38, Issue 1, 2015, Pages 59-65

  Kowall, Bernd ^a   Rathmann, Wolfgang ^a   Kostev, Karel ^b  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; METFORMIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DATA BASE; DRUG EXPOSURE; FEMALE; FOLLOW UP; GERMAN DISEASE ANALYZER DATABASE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 84919980137     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0977     Document Type: Article

References (26)

1. Seshasai SR, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of causespecific death. N Engl J Med 2011;364:829-841
2. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A metaanalysis. Int J Cancer 2007;121:856-862
3. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: A meta-analysis. Diabetologia 2007;50:1365-1374
4. Larsson SC, Orsini N,Wolk A. Diabetesmellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst 2005;97:1679-1687
5. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3:1451-1461
6. Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: A meta-analysis. Oncologist 2012;17:813-822
7. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. PLoS ONE 2012;7:e33411
8. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: A meta-analysis. Cancer Epidemiol 2013;37:207-218
9. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: A meta-analysis using primary data of published studies. Metabolism 2013;62:922-934
10. Suissa S, Azoulay L. Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care 2012;35:2665-2673
11. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G; ADOPT Study Group; RECORD Steering Committee. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010;53: 1838-1845
12. Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: Systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012;55:2593-2603
13. Suissa S, Azoulay L. Metformin and cancer: mounting evidence against an association. Diabetes Care 2014;37:1786-1788
14. Suissa S. Immortal time bias in pharmacoepidemiology. AmJ Epidemiol 2008;167:492-499
15. Rathmann W, Schloot NC, Kostev K, Reaney M, Zagar AJ, Haupt A. Macro-and microvascular outcomes in patients with type 2 diabetes treated with rapid-acting insulin analogues or human regular insulin: A retrospective database analysis. Exp Clin Endocrinol Diabetes 2014;122: 92-99
16. Kostev K, Jockwig A, Hallwachs A, Rathmann W. Prevalence and risk factors of neuropathy in newly diagnosed type 2 diabetes in primary care practices: A retrospective database analysis in Germany and UK. Prim Care Diabetes 2014;8:250-255
17. Rathmann W, Kostev K, Gruenberger JB, Dworak M,BaderG,GianiG. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: A primary care database analysis. Diabetes Obes Metab 2013;15: 55-61
18. Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 2009;47: 617-626
19. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-1139
20. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 2000;21:552-560
21. German Centre for Cancer Registry Data. Berlin, Germany, Robert Koch Institute. Available from http://www.rki.de/Krebs/SiteGlobals/ Forms/Datenbankabfrage/datenbankabfrage-stufe2-form.html. Accessed 8 April 2014
22. Stricker BH, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 2010;25:245-251
23. Smiechowski B, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiol Biomarkers Prev 2013;22:1877-1883
24. Ferrara A, Lewis JD, Quesenberry CP Jr, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011;34:923-929
25. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large population-based follow-up study. Diabetes Care 2012;35:119-124
26. Mamtani R, Pfanzelter N, Haynes K, et al. Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care 2014;37:1910-1917